AstraZeneca PLC has won the initial battle over its antipsychotic drug Seroquel, removing the threat of generic competition for the company's second-best-selling product with $4 billion in sales in 2007 after Nexium.
In addition to this AstraZeneca PLC has also sued Sandoz for filing ANDA. Both Teva and Sandoz are in race for generic version of Seroquel and seek approval to market generic versions of SEROQUEL® (quetiapine fumarate tablets) in the US before SEROQUEL's US patent 4879288 expires in Sep. 2011.
For further details refer Wall Street journal and CNN money at
http://online.wsj.com/article/SB121495435431321131.html?mod=googlenews_wsj
http://money.cnn.com/news/newsfeeds/articles/apwire/851476d46341f0e43802c566ca32b121.htm
In addition to this AstraZeneca PLC has also sued Sandoz for filing ANDA. Both Teva and Sandoz are in race for generic version of Seroquel and seek approval to market generic versions of SEROQUEL® (quetiapine fumarate tablets) in the US before SEROQUEL's US patent 4879288 expires in Sep. 2011.
For further details refer Wall Street journal and CNN money at
http://online.wsj.com/article/SB121495435431321131.html?mod=googlenews_wsj
http://money.cnn.com/news/newsfeeds/articles/apwire/851476d46341f0e43802c566ca32b121.htm
No comments:
Post a Comment